News

A recent survey reveals how generational differences affect consumers’ health plan and provider preferences and selections.

Creating a national data policy framework for empowered consumer choices.

With new requirements from CMS on the horizon, how will the shift to value-based care impact consumers, payers, and providers?

FDA issued a new warning about potentially serious side effects associated with fluoroquinolone antibacterial drugs. Affected brands include Cipro, Levaquin, Avelox, Factive and Moxaflaxacin injection, as well as the generic Ofloxacin.

As pharmaceutical companies of all sizes continue to adapt to the ongoing internal and external pressures of the new health economy, it remains imperative that strategy maintain distinct capabilities to position the company ahead of its competitors.

Insights from the 2016 edition of the largest gathering in specialty pharmacy.

Hep C virus testing supports value of diagnostics in precision medicine.

FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body.

MACRA, which will further the shift to value-based reimbursement, has industry insiders grappling with the complexities, particularly those related to reporting guidelines for providers.

An expansion of the ACA requires health plans to cover a new preventive service: Regular nutritional counseling for millions of overweight Americans with other health risks.

Health insurance coverage remains a huge challenge for small businesses due to cost. Health plan providers and brokers are in a unique position to address these challenges and target the working uninsured with affordable options for coverage.

Colorado could have the first statewide universal healthcare system in the country if proposed legislation passes in November. Will it happen? Experts weigh in.

Insight from Paul Markovich, CEO, Blue Shield of California

Looking back on your career, what advice do you wish you had starting out? Here’s what our editorial advisory board said.

FDA recently fast-tracked approval of cabozantinib (Cabometyx, Exelixis, Inc.) to treat advanced renal cell carcinoma. Here are the top 5 facts to know about Cabometyx.

Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.

Express Scripts will implement more programs that pay for drugs based on their effectiveness, according to the PBM’s chief medical officer Steve Miller, MD. Simultaneously, the PBM plans to implement a spending cap on diabetes medications.

Doug Chaet, senior vice president, Provider Networks and Value-Based Solutions at Independence Blue Cross, shares five strategies that can help providers succeed in value-based reimbursement models.

Democratic presidential candidate Hillary Clinton vows to provide more affordable, cost effective, accessible, and higher quality healthcare and insurance coverage. Here’s a closer look at seven key ways Clinton would change the healthcare system if elected president.

FDA approved the first drug to hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.

Drug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.

Hospitalizations represent up to 80 percent of the direct medical costs of heart failure; reducing heart failure hospitalizations can help bring down overall healthcare costs.

A look at how Trump's specific plans for healthcare could impact the industry.

The first US test for the Zika virus is available after Quest Diagnostics received an Emergency Use Authorization (EUA) for its Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test).

Though technology companies are continuing to innovate in the wearable field, healthcare organizations are slow to adapt.

FDA recently approved a new indication for afatinib (Gilotrif, Boehringer Ingelheim) for patients with squamous cell carcinoma of the lung. The once-daily tablets are now indicated for the treatment of patients with the lung cancer, whose disease has progressed after treatment with platinum-based chemotherapy. Here are the top 6 facts to know about Gilotrif.

A look at how each GOP candidate’s specific plans for healthcare could impact the industry.

New regulations will check the drive to narrow networks, just as the business case for forming them grows more compelling.

Personalization is the key to a healthcare experience that optimizes outcomes, improves the customer experience and, ultimately, lowers costs to the healthcare system. Find out why it’s especially key for diabetic patients.